The hypolipidemic activity of Ayurvedic medicine, Arogyavardhini vati in Triton WR-1339-induced hyperlipidemic rats: A comparison with fenofibrate

Abstract

Background:Hyperlipidemia is a major risk factor of coronary heart disease. Currently available hypolipidemic drugs have been associated with number of side effects. Arogyavardhini vati, an Ayurvedic polyherbal formulation has been used for liver disorders. Therefore, present study was designed to evaluate the effect of Arogyavardhini vati in Triton WR-1339-induced hyperlipidemia in rats.Objectives:Anti-hyperlipidemic activity evaluation of Arogyavardhini vati against Triton WR-1339-induced hyperlipidemia in rats.Materials and Methods:Overnight fasted male Wistar rats (150-200 g) were randomly divided into normal control group [4% Dimethyl Sulfoxide (DMSO), i.p.], positive control group (Triton WR-1339 in 4% DMSO, 400 mg/kg, i.p.), standard drug treated (fenofibrate 65 mg/kg, p.o. for 7 days after inducing hyperlipidemia) and Arogyavardhini vati treated (50, 100, 200 mg/kg, p.o. for 7 days after inducing hyperlipidemia). Rat doses were calculated by extrapolating the equivalent human dose (therapeutic dose, sub-maximum, and maximum dose). Serum total cholesterol, triglyceride, low-density lipoprotein (LDL), high-density lipoprotein HDL, liver malondialdehyde (MDA), and glutathione (GSH) levels were estimated at end of experiments.Results:Arogyavardhini vati significantly decreased serum cholesterol, triglyceride, LDL, and C-reactive protein (CRP) and significantly increased serum HDL in a dose-dependent manner. Decreased MDA and increased GSH levels in liver were observed at all doses of Arogyavardhini vati (50, 100, 200 mg/kg) and fenofibrate-treated groups when compared with Triton-treated group. Atherogenic Index (AI) level was significantly decreased in fenofibrate and Arogyavardhini vati (200 mg/kg) treated rats when compared with normal control.Conclusion:Arogyavardhini vati, a traditionally used Ayurvedic medicine may be a useful therapy for hypercholesterolemia through reducing oxidative stress (decreasing MDA and increasing GSH) and lipid levels.

Pharmacological evaluation of Convolvulus pluricaulis as hypolipidaemic agent in Triton WR-1339-induced hyperlipidaemia in rats

“…Fenofibrate 65 mg/kg group showed statistically significant decrease in TC, TG levels with non‐significant increase in HDL‐c but no effect on LDL‐c. These results were similar to previous studies showing hypolipidaemic activity of a standard drug fenofibrate in earlier studies . Triton WR‐1339, the nonionic detergent, is a well‐known induction agent for hypercholesterolaemia in rat was selected for inducing rapid, easy and reversible (span of 1 week) hyperlipidaemia in the experimental rats.…”

“…standard drug fenofibrate in earlier studies. [1,22] Triton WR-1339, the nonionic detergent, is a well-known induction agent for hypercholesterolaemia in rat was selected for inducing rapid, easy and reversible (span of 1 week) hyperlipidaemia in the experimental rats. It leads to the accumulation of VLDL and triglycerides in plasma by inhibiting the enzyme lipoprotein lipase.…”

“…Hyperlipidaemia has arisen as a significant risk factor for cardiovascular disorders worldwide during the last three decades . Reducing the levels of atherogenic lipids within acceptable margin has been established by numerous animal experiments and clinical trials demonstrating decrease in cardiovascular mortality and morbidity .…”

“…Hyperlipidaemia has arisen as a significant risk factor for cardiovascular disorders worldwide during the last three decades. [1,2] Reducing the levels of atherogenic lipids within acceptable margin has been established by numerous animal experiments and clinical trials demonstrating decrease in cardiovascular mortality and morbidity. [3] The current treatment options for hyperlipidaemia mainly include statins, fibrate, nicotinic acid, bile acid binding resins, and the same are associated with significant number of side effects.…”

Evaluation of in vitro antioxidant and anti-atherogenic properties of selected Siddha polyherbal decoctions

“…Same information was noted in a Siddha review article of Kanakavalli et al (2014). The hypo lipidemic drugs created one more major problem that is renal failure (Gupta et al, 2013). But herbals have a most important task in anti-hyper lipidemic activity and recommend that the lipid reducing action is decided through stimulating of liver cholesterol biosynthesis and decrease of lipid absorption in the intestine (Kanakavalli et al, 2014).…”